(NASDAQ: MREO) Mereo Biopharma Group's forecast annual revenue growth rate of 282.74% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.07%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.06%.
Mereo Biopharma Group's revenue in 2026 is $500,000.On average, 8 Wall Street analysts forecast MREO's revenue for 2026 to be $2,889,894,912, with the lowest MREO revenue forecast at $0, and the highest MREO revenue forecast at $5,949,783,643. On average, 8 Wall Street analysts forecast MREO's revenue for 2027 to be $37,640,462,234, with the lowest MREO revenue forecast at $234,639,355, and the highest MREO revenue forecast at $87,702,444,605.
In 2028, MREO is forecast to generate $9,036,009,444 in revenue, with the lowest revenue forecast at $8,681,656,133 and the highest revenue forecast at $9,301,774,428.